In spring 2009, a new pandemic swine-origin influenza A (H1N1) virus emerged in Mexico [1] and the United States [2] and spread globally thereafter. Although the infection proved to be uncomplicated in the majority of cases, severe complications and fatal outcomes have been reported. Risk factors predictive for complications include younger age (children !2 years), pregnancy, obesity, pulmonary or other comorbid conditions, and concurrent immunosuppression [3, 4] . On the basis of data from seasonal influenza, it has been postulated that patients infected with human immunodeficiency virus type 1 (HIV-1), especially those with low CD4 cell counts or advanced stage of disease, might be at increased risk for H1N1 influenza-related complications [5, 6] . Data on the clinical course of 2009 H1N1 influenza in HIV-1-infected children and adolescents have not yet been published. We describe an outbreak of 2009 H1N1 influenza among a group of 15 HIV-1-infected school-aged children in Germany, which allowed systematic monitoring of clinical features, kinetics of viral shedding, and development of H1N1-specific antibodies in these patients.
Methods. Fifteen perinatally HIV-1-infected children and adolescents, all patients at the pediatric outpatient HIV clinic, Charité, Berlin, Germany, participated in a 7-day trip to a youth camp in Germany in October 2009. All were treated with highly active antiretroviral therapy. Eleven patients (73%) had an HIV-1 load !20 copies/mL, and all had CD4 counts 1350 cells/mL. Comorbid conditions (mild asthma) were present in 2 children. No patient had been vaccinated against 2009 H1N1 influenza because the vaccine was not available at this time. Baseline characteristics are summarized in Table 1 .
On a second day of travel, a 16-year-old boy (patient I) had to be hospitalized for high-grade fevers and cough, which retrospectively was the first case of 2009 H1N1 influenza in the group. On the last day of the trip, 3 children developed an acute illness with high-grade fevers and influenza-like symptoms and subsequently received a diagnosis of 2009 H1N1 influenza virus infection by reverse transcriptase polymerase chain reaction (RT-PCR) assay of nasal swabs. After parental consent and approval by the institutional ethics committee, all 15 patients were closely monitored as outpatients.
Data on patients' demographic characteristics and medical history were obtained from review of medical records. Time and quality of influenza-related symptoms at onset were documented as reported by patients and their camp supervisors. During follow-up visits, scheduled every other day, disease symptoms were recorded, physical examinations were performed, and nasal swabs were collected and processed immediately for virological analysis. After documentation of 2 consecutively negative RT-PCR results from nasal swabs, monitoring and contact isolation at home were discontinued.
Virus isolation was performed on Madin-Darby canine kidney SIAT-1 cells as described elsewhere [7] . Viral RNA was extracted from nasal swabs, and the specific 2009 H1N1 influenza RNA was amplified as described elsewhere [8] . 2009 H1N1 influenza-specific antibody titers of probes obtained ∼6 weeks after the onset of symptoms were compared with those from cryopreserved serum samples collected during routine clinic visits prior to the trip (baseline). Antibodies were determined ). This resulted in an attack rate of 100%. n p 14 Fourteen of 15 patients became symptomatic, all within a 7-day period. The most common symptoms were fever, cough, and fatigue (Table 1) . Mild symptoms, mostly low-grade fevers (138ЊC to 39ЊC) for !24 h and cough, occurred in 8 children. Five patients, who presented with high-grade fever (139ЊC), cough, and fatigue received antiviral treatment with oseltamivir Table 2 . Blood cell counts during influenza infection were available in 6 patients. Even though 5 patients had a transient neutropenia (!1500 neutrophils/mL), severe lymphopenia (р800 lymphocytes/mL) was not observed.
Nasal swabs were available from all 15 patients; the first specimen was collected at a median of 3 days (range, 1-9 days) after onset of symptoms. Initial samples from 11 patients (73%) had positive results by RT-PCR; all of them also had positive culture results. The median time from onset of symptoms to first negative RT-PCR result was 9 days (range, 5-14 days), whereas culture results became negative after 6 days (range, 3-11 days). Four patients who had negative results by RT-PCR also had negative results by culture.
Because of more severe initial symptoms, 5 patients received antiviral therapy with oseltamivir. There was a significant difference in the duration of viral shedding in oseltamivir-treated versus untreated patients; among oseltamivir-treated children, 2009 H1N1-specific RNA was detected for a median of 4 days (range, 4-5 days), compared with 8 days (range, 8-13 days) among untreated patients ( ). Virus was detectable by P p .005 culture for a median of 3 days (range, 2-3 days) among oseltamivir-treated patients, compared with 6 days (range, 5-10 days) among untreated patients ( ). P p .005 Comparative serum samples were available for 14 patients. Although all baseline probes were antibody negative, all followup samples had positive results (median titer, 1:40; range, 1: 10 to 1:320), including samples from patients who had negative results by RT-PCR or culture. Eleven (79%) of 14 patients had an antibody titer of у1:40 (Table 2) .
Discussion. All 15 participants in a travel group of HIV-1-infected school-aged patients were found to be infected with 2009 H1N1 influenza virus, which emphasizes the high level of contagiosity of the virus in this setting. This observation is in contrast to the relatively low transmissibility of the 2009 H1N1 influenza virus reported among immunocompetent household contacts [9] and may be explained by the very close contact of the children during the trip. According to current Centers for Disease Control and Prevention guidelines, patients with HIV-1 infection or other forms of immunodeficiency are considered to be at risk for complications of 2009 H1N1 influenza [10] . However, our observations revealed a mostly selflimited and mild clinical course with clinical features similar to those reported in the general pediatric population [4, 11, 12] . Relatively few patients in our cohort had fever (10 [67%] of 15 children), compared with the incidence reported among mostly immunocompetent children with 2009 H1N1 influenza (88% [12] to 95% [11] ). This may be explained by the fact that these studies included mostly hospitalized patients. Severe lymphopenia (р800 lymphocytes/mL), which may be a predictor for respiratory failure [13] , was not observed among our patients.
The benign clinical course in this HIV-1-infected population may be explained by the lack of severe immunodeficiency attributable to successful antiretroviral treatment, the absence of relevant comorbidities, and in light of an underlying chronic disease, increased awareness by patients and care providers, leading to earlier diagnosis and intervention.
Studies of seasonal influenza [14] and 2009 H1N1 influenza [15] have indicated that viral shedding might be prolonged in immunocompromised patients. Aside from an anecdotal report [16] , very little is known about the duration of viral shedding after influenza infection in HIV-1-infected patients. In our cohort, viral shedding lasted a median of 8 and 5 days, measured by RT-PCR and culture, respectively, which was similar to published reports in general populations [17, 18] . Because early antiviral treatment with oseltamivir resulted in a significantly shorter duration of viral shedding, this treatment may not only mitigate symptoms but may also reduce transmissions to susceptible household members who may be at increased risk of complications (eg, because of HIV-1 infection with advanced immunodeficiency) [19] .
It has been hypothesized that immunocompromised patients may not develop protective immunity after 2009 H1N1 influenza infection. In our study group, all patients tested developed 2009 H1N1-specific antibodies. Whether this confers long lasting protection remains to be determined. However, 11 of 14 patients had a hemagglutination inhibition antibody titer of у1:40, which is considered to be protective in vaccine studies [20] .
In conclusion, the clinical course of 2009 H1N1 influenza among HIV-1-infected school-aged children with CD4 counts 1350 cells/mL receiving highly active antiretroviral therapy did not differ from that described for healthy children. Viral shedding was not prolonged and could be further shortened by early neuraminidase inhibitor treatment, and the humoral immune response seems to be preserved. However, the same may not apply for HIV-1-infected patients with advanced immunodeficiency and/or comorbid conditions and for those living in areas with restricted access to medical care. Therefore, in accordance with current recommendations, HIV-1-infected patients should be vaccinated, and in cases of suspected influenza infection, an empirical early antiviral treatment is strongly advised.
